| DIRECT COMPETITOR COMPARISON | |
| SYI | AMLN | NVS | PFE | Industry | | Market Cap: | N/A | 1.95B | 125.67B | 143.31B | N/A | | Employees: | N/A | 1,800 | 99,000 | 81,800 | N/A | | Qtrly Rev Growth (yoy): | N/A | -3.30% | 2.40% | -2.90% | N/A | | Revenue (ttm): | N/A | 816.77M | 42.31B | 45.82B | N/A | | Gross Margin (ttm): | N/A | 59.56% | 72.61% | 86.61% | N/A | | EBITDA (ttm): | N/A | -125.22M | 11.24B | 21.31B | N/A | | Oper Margins (ttm): | N/A | -19.59% | 21.50% | 37.42% | N/A | | Net Income (ttm): | N/A | -234.68M | 7.59B | 8.09B | N/A | | EPS (ttm): | N/A | -1.680 | 3.34 | 1.204 | N/A | | P/E (ttm): | N/A | N/A | 16.57 | 14.75 | N/A | | PEG (5 yr expected): | N/A | N/A | 2.87 | 5.82 | N/A | | P/S (ttm): | N/A | 2.41 | 2.98 | 3.18 | N/A |
|
| AMLN = Amylin Pharmaceuticals, Inc. | | NVS = Novartis AG | | PFE = Pfizer Inc. | |
| NEWS ON DIRECT COMPETITORS | |
|
|
|